CD274 and hepatocellular carcinoma: These PDX mice treated with combined ATRA+HDACi+anti‐PDL1 survived for six months after PDX implantation (Figure 3L), indicating that this combination therapy effectively suppressed recurrence and was effective even for standard‐care‐drug sorafenib‐resistant HCC.